Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Farmers Insurance
Chinese Patent Office
Deloitte
Dow
Accenture
Cantor Fitzgerald
Novartis
Argus Health
Fuji
Daiichi Sankyo

Generated: October 23, 2017

DrugPatentWatch Database Preview

Details for Patent: 7,723,305

« Back to Dashboard

Which drugs does patent 7,723,305 protect, and when does it expire?


Patent 7,723,305 protects VYVANSE and is included in two NDAs. There has been one Paragraph IV challenge on Vyvanse.

This patent has one hundred and forty-four patent family members in twenty-six countries.

Summary for Patent: 7,723,305

Title:Abuse-resistant amphetamine prodrugs
Abstract:The invention describes compounds, compositions, and methods of using the same comprising a chemical moiety covalently attached to amphetamine. These compounds and compositions are useful for reducing or preventing abuse and overdose of amphetamine. These compounds and compositions find particular use in providing an abuse-resistant alternative treatment for certain disorders, such as attention deficit hyperactivity disorder (ADHD), ADD, narcolepsy, and obesity. Oral bioavailability of amphetamine is maintained at therapeutically useful doses. At higher doses bioavailability is substantially reduced, thereby providing a method of reducing oral abuse liability. Further, compounds and compositions of the invention decrease the bioavailability of amphetamine by parenteral routes, such as intravenous or intranasal administration, further limiting their abuse liability.
Inventor(s): Mickle; Travis (Coralville, IA), Krishnan; Suma (Belvedere, CA), Bishop; Barney (Annandale, VA), Lauderback; Christopher (Blacksburg, VA), Moncrief; James Scott (Christiansburg, VA), Oberlender; Robert (Blacksburg, VA), Piccariello; Thomas (Blacksburg, VA), Paul; Bernhard J. (Lexington, MA), Verbicky; Christopher A. (Broadalbin, NY)
Assignee: Shire LLC (Florence, KY)
Application Number:12/202,003
Patent Claim Types:
see list of patent claims
Composition; Formulation; Dosage form; Use;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Shire Dev Llc
VYVANSE
lisdexamfetamine dimesylate
TABLET, CHEWABLE;ORAL208510-001Jan 28, 2017RXYesNo► Subscribe► SubscribeY FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Shire Dev Llc
VYVANSE
lisdexamfetamine dimesylate
TABLET, CHEWABLE;ORAL208510-002Jan 28, 2017RXYesNo► Subscribe► SubscribeY FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Shire Dev Llc
VYVANSE
lisdexamfetamine dimesylate
TABLET, CHEWABLE;ORAL208510-003Jan 28, 2017RXYesNo► Subscribe► SubscribeY FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Shire Dev Llc
VYVANSE
lisdexamfetamine dimesylate
TABLET, CHEWABLE;ORAL208510-004Jan 28, 2017RXYesNo► Subscribe► SubscribeY FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Shire Dev Llc
VYVANSE
lisdexamfetamine dimesylate
TABLET, CHEWABLE;ORAL208510-005Jan 28, 2017RXYesNo► Subscribe► SubscribeY FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Shire Dev Llc
VYVANSE
lisdexamfetamine dimesylate
TABLET, CHEWABLE;ORAL208510-006Jan 28, 2017RXYesYes► Subscribe► SubscribeY FOR THE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD)
Shire Development
VYVANSE
lisdexamfetamine dimesylate
CAPSULE;ORAL021977-004Dec 10, 2007RXYesNo► Subscribe► SubscribeY INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
Shire Development
VYVANSE
lisdexamfetamine dimesylate
CAPSULE;ORAL021977-001Feb 23, 2007RXYesNo► Subscribe► SubscribeY INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
Shire Development
VYVANSE
lisdexamfetamine dimesylate
CAPSULE;ORAL021977-005Dec 10, 2007RXYesNo► Subscribe► SubscribeY INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
Shire Development
VYVANSE
lisdexamfetamine dimesylate
CAPSULE;ORAL021977-002Feb 23, 2007RXYesNo► Subscribe► SubscribeY INDICATED FOR THE TREATMENT OF ATTENTION-DEFICIT/HYPERACTIVITY DISORDER (ADHD)
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 7,723,305

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,674,774Abuse-resistant amphetamine prodrugs► Subscribe
8,343,927Pharmaceutical compositions for prevention of overdose or abuse► Subscribe
7,662,788Abuse-resistant amphetamine prodrugs► Subscribe
7,713,936Abuse-resistant amphetamine prodrugs► Subscribe
6,716,452 Active agent delivery systems and methods for protecting and administering active agents► Subscribe
8,106,016Compounds and compositions for prevention of overdose of oxycodone► Subscribe
7,375,083Pharmaceutical compositions for prevention of overdose or abuse► Subscribe
7,700,561Abuse-resistant amphetamine prodrugs► Subscribe
8,394,813Active agent delivery systems and methods for protecting and administering active agents► Subscribe
8,133,881Carbohydrate conjugates to prevent abuse of controlled substances► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 7,723,305

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria462411► Subscribe
Austria462412► Subscribe
Austria519502► Subscribe
Austria533512► Subscribe
Austria545427► Subscribe
Australia2001286599► Subscribe
Australia2001297565► Subscribe
Australia2001298033► Subscribe
Australia2003216382► Subscribe
Australia2003217676► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
McKinsey
Teva
Accenture
AstraZeneca
Queensland Health
Chinese Patent Office
Medtronic
UBS
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot